Cohance Lifesciences Invests $10M in US Subsidiary NJ Bio

Cohance Lifesciences Ltd has completed a $10 million investment in its US-based subsidiary, NJ Bio Inc., through the subscription of Compulsorily Convertible Preferred Stock (CCPS). This funding is intended to support NJ Bio's growth initiatives, particularly in the Antibody Drug Conjugate (ADC) and broader 'XDC' space. NJ Bio operates as a Contract Research, Development, and Manufacturing Organization (CRDMO) with end-to-end capabilities in ADC development. The transaction, classified as a related party transaction at arm's length, is expected to be completed by the end of September 2026. This strategic investment reinforces Cohance's commitment to the high-growth ADC sector.